Why I built LLMGauntlet

Today's LLMs are built on statistical inference. They predict the next token from patterns in their training data — they don't reason about cause and effect. That's a fundamental limitation, and in low-stakes contexts (chat, summarization, autocomplete), nobody notices.

But in healthcare, finance, justice, defense — anywhere a model's output has real-world consequences — the absence of causal reasoning becomes a liability. A model that confuses correlation with causation in a credit risk decision, a medical triage, or a sentencing recommendation isn't just inaccurate. It's dangerous.

The “one model fits all” era is ending. The future isn't a single trillion-parameter generalist serving every industry. It's thousands of specialized models — forks of the giants' foundation models, each fine-tuned on domain-specific data, deployed on narrow vertical use cases. Each enterprise will train and operate its own.

Which means evaluation has to follow. Generic benchmarks won't tell you whether your model — trained on your data, deployed in your vertical — actually reasons causally about your domain. You need a causal evaluation built for your structure, not someone else's.

That's what we do. The public benchmark you see on this site — 16 models, 3 causal DAGs, 169 unit tests — validates our methodology. The findings (only 1 of 16 models is world-invariant; 81% are pattern-matching, not reasoning) are not a sales pitch. They're proof that our framework catches real causal flaws at scale.

What we offer commercially: the same methodology, applied to your domain. We build a custom causal world — mediator, collider, confounder — that maps to your vertical, evaluate your model (or your candidates), and deliver a report that tells you whether your stack is truly reasoning or merely confident.

If you're shipping a domain-specific LLM into production — in health, finance, public sector, anywhere causality matters — you should be testing it for causal flaws. Not because LLMGauntlet says so. Because the cost of not testing it is asymmetric. Generic accuracy hides catastrophic specific failures.

If that's where you are, let's talk. We're in active discussions with European financial institutions, and we have bandwidth for 2-3 more pilot engagements this quarter.